Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMI1 | P35226 | 10/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.35 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.35 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16739554 | 0.90 | BMI1 (0.49) | BMI1DHODHGRM5AGPAT2KCNH3 | |
| SCHEMBL16740143 | 0.89 | BMI1 (0.43) | BMI1 | |
| SCHEMBL16747853 | 0.88 | BMI1 (0.66) | BMI1DHODH | |
| SCHEMBL16739717 | 0.87 | EGFR (0.40) | BMI1GRM5AGPAT2 | |
| SCHEMBL16747852 | 0.86 | DHFR (0.43) | BMI1 | |
| SCHEMBL16747858 | 0.86 | BMI1 (0.55) | BMI1DHODHAGPAT2 | |
| SCHEMBL29820520 | 0.86 | BMI1 (0.55) | BMI1DHODHAGPAT2 | |
| SCHEMBL16739733 | 0.85 | BMI1 (0.65) | BMI1DHODHKCNH3 | |
| SCHEMBL16747817 | 0.85 | BMI1 (0.49) | BMI1DHODHAGPAT2 | |
| SCHEMBL16739724 | 0.85 | TUBB4A (0.47) | BMI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | claimed |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | BMI1 1/4885DHODH 3196/4885GRM5 2299/4885 |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | BMI1, BAZ2A, BAZ2B | BMI1 1/4885DHODH 3196/4885GRM5 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.